Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Daniel D. De Carvalho"'
Publikováno v:
Cancer Discovery. 11:2707-2725
Features of the cancer epigenome distinguish cancers from their respective cell of origin and establish therapeutic vulnerabilities that can be exploited through pharmacologic inhibition of DNA- or histone-modifying enzymes. Epigenetic therapies conv
Autor:
Thomas Kislinger, Jeffrey Zuccato, Shahbaz Khan, Yasin Mamatjan, Sébastien Froelich, Gelareh Zadeh, Namita Sinha, Shirin Karimi, Olivia Singh, Jeffrey C Liu, Ankur Chakravarthy, Anne-Laure Bernat, Joao Paulo Almeida, Homa Adle-Biassette, Farshad Nassiri, Sheila Mansouri, Vikas Patil, Kenneth Aldape, Mohammed Hasen, Daniel D. De Carvalho
Publikováno v:
Neuro Oncol
Background Chordomas are rare malignant bone cancers of the skull-base and spine. Patient survival is variable and not reliably predicted using clinical factors or molecular features. This study identifies prognostic epigenetic chordoma subtypes that
Autor:
Helen Loo Yau, Parinaz Mehdipour, Ilias Ettayebi, Charles A. Ishak, Ankur Chakravarthy, Daniel D. De Carvalho, Catherine A. O’Brien, Amir H. Hosseini, Fabíola Attié de Castro, Yadong Wang, Sagi Abelson, Sajid A. Marhon
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
Cancer therapies that target epigenetic repressors can mediate their effects by activating retroelements within the human genome. Retroelement transcripts can form double-stranded RNA (dsRNA) that activates the MDA5 pattern recognition receptor1–6.
Autor:
Wail Ba-alawi, Evelyne Lima-Fernandes, Jason W. Locasale, Daniel D. De Carvalho, Paul Savage, Ilias Ettayebi, Hellen Kuasne, Morag Park, Felicia Tai, Yunchi Ingrid Kao, Benjamin Haibe-Kains, Alexandra N. Fedor, Paul Guilhamon, Giacomo Grillo, Seyed Ali Madani Tonekaboni, Cheryl H. Arrowsmith, Xiaojing Liu, Constanza Martinez, Anne-Marie Fortier, Mathieu Lupien, Alex Murison, Geneviève Deblois, David W. Cescon
Publikováno v:
Cancer Discovery. 10:1312-1329
Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant
Autor:
Karan J. Abraham, Miling Wang, Jack Greenblatt, Lauren A. Ostrowski, Aparna Gorthi, Parasvi S. Patel, Daniel D. De Carvalho, Razq Hakem, Michael Ohh, Roxanne Oshidari, Alexander J.R. Bishop, Violena Pietrobon, Anas Samman, Arash Algouneh, Dorothy Yanling Zhao, Stephen Lee, Michael Bokros, Janet N.Y. Chan, V Talya Yerlici, Rajat Singhania, Brendan C. Dickson, Yupeng Liu, Elva Vidya, Negin Khosraviani, Karim Mekhail
Publikováno v:
Nature
Proteins are manufactured by ribosomes—macromolecular complexes of protein and RNA molecules that are assembled within major nuclear compartments called nucleoli1,2. Existing models suggest that RNA polymerases I and III (Pol I and Pol III) are the
Publikováno v:
Annual Review of Cancer Biology. 4:159-176
Domesticated retroelements contribute extensively as regulatory elements within host gene networks. Upon germline integration, retroelement mobilization is restricted through epigenetic silencing, mutational degradation, and innate immune defenses de
Publikováno v:
Immunity. 54:11-13
In a recent issue of Cell, Bowling et al. describe a mechanism by which spliceosome-targeted therapies result in intron-containing transcripts that form double-stranded RNAs (dsRNAs), thereby activating tumor antiviral signaling (viral mimicry) and d
Publikováno v:
Clin Cancer Res
PURPOSE. Ovarian cancer is a heterogeneous disease that can be divided into multiple subtypes with variable etiology, pathogenesis, and prognosis. We analyzed DNA methylation profiling data to identify biologic subgroups of ovarian cancer and study t
Publikováno v:
Nature Reviews Cancer. 19:151-161
DNA methylation inhibitors have become the mainstay for treatment of certain haematological malignancies. In addition to their abilities to reactivate genes, including tumour suppressors, that have acquired DNA methylation during carcinogenesis, they
Publikováno v:
Trends in Cell Biology. 29:31-43
During cancer initiation and progression, the somatic epigenome is broadly reprogrammed. This reprogramming can be a consequence of several processes, including altered transcriptional profiles and mutations. In addition, immune cells infiltrating th